...
首页> 外文期刊>Oncology research and treatment. >Natural Killer/T Cell Lymphoma, Nasal Type: A Retrospective Clinical Analysis in North-Western China
【24h】

Natural Killer/T Cell Lymphoma, Nasal Type: A Retrospective Clinical Analysis in North-Western China

机译:鼻型自然杀伤/ T细胞淋巴瘤:中国西北地区的回顾性临床分析

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Extranodal natural killer (NK)/T cell lymphoma (ENKTL) is an aggressive non-Hodgkin's lymphoma with high mortality and poor prognosis despite radiotherapy and chemotherapy. The current analysis aimed to assess the pathological features, clinical features, and prognostic indicators of ENKTL. Material and Methods: 120 ENKTL patients were analyzed for pathologic diagnosis and clinical disease manifestations from April 2007 to October 2012. Complete remission, 2-year overall survival, and progression-free survival were analyzed. Results: Compared with the nasal group, a greater percentage of patients in the non-nasal group intended to receive autologous stem cell transplantation had Epstein-Barr virus (EBV) DNA, Ann Arbor stage IV, Ki-67 expression >= 60%, and abnormal ferroprotein and beta-microglobulin levels. The rate of complete remission in the non-nasal group was higher than that in the nasal group. The overall survival rate was 74.9% at 24 months. Patients receiving chemotherapy and radiotherapy were more likely to have disease progression compared with patients who received chemotherapy or radiotherapy alone. Conclusions: Further understanding the pathological and clinical features of ENKTL will be critical for moving forward. Ki-67, beta-microglobulin, EBV DNA, and primary site prognostic indicators may be useful to stratify patients into different risk groups, to gain insight into patient-specific treatments, and to potentially improve survival. (C) 2016 S. Karger GmbH, Freiburg
机译:背景:结外自然杀手(NK)/ T细胞淋巴瘤(ENKTL)是一种侵袭性非霍奇金淋巴瘤,尽管放疗和化疗,但死亡率高,预后差。目前的分析旨在评估ENKTL的病理特征,临床特征和预后指标。材料与方法:分析2007年4月至2012年10月期间120例ENKTL患者的病理诊断和临床疾病表现。分析了完全缓解,2年总生存期和无进展生存期。结果:与鼻腔治疗组相比,非鼻腔治疗组中打算接受自体干细胞移植的患者中有更大比例的患者具有爱泼斯坦-巴尔病毒(EBV)DNA,安阿伯阶段IV,Ki-67表达> = 60%,以及异常的铁蛋白和β-微球蛋白水平。非鼻腔组的完全缓解率高于鼻腔组。 24个月时总生存率为74.9%。与仅接受化学疗法或放射疗法的患者相比,接受化学疗法和放射疗法的患者更容易发生疾病。结论:进一步了解ENKTL的病理和临床特征对于向前发展至关重要。 Ki-67,β-微球蛋白,EBV DNA和主要部位预后指标可能有助于将患者分为不同的风险组,深入了解针对患者的治疗方法,并可能提高生存率。 (C)2016 S.Karger GmbH,弗赖堡

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号